Search Results - "SAVEN, A"

Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma by Piro, L. D., White, C. A., Grillo-López, A. J., Janakiraman, N., Saven, A., Beck, T. M., Varns, C., Shuey, S., Czuczman, M., Lynch, J. W., Kolit, J. E., Jain, V.

“…Background: Rituximab is a chimeric monoclonal antibody directed against the B-cell CD20 antigen which has been utilized for therapy of B-cell non-Hodgkin's…”
Get full text

The Scripps Clinic experience with cladribine (2-CdA) in the treatment of chronic lymphocytic leukemia by Saven, A

Get more information

2-Chlorodeoxyadenosine treatment of low-grade lymphomas by Kay, A C, Saven, A, Carrera, C J, Carson, D A, Thurston, D, Beutler, E, Piro, L D

“…Because of the need to identify effective new agents in the treatment of non-Hodgkin's lymphoma and because of the high activity of the purine analog…”
Get more information

Enzyme Replacement Therapy for Gaucher Disease by Beutler, E., Kay, A., Saven, A., Garver, P., Thurston, D., Dawson, A., Rosenbloom, B.

“…Four patients with moderately severe type I Gaucher disease were treated with commercially available mannose terminated glucocerebrosidase (Ceredase; Genzyme,…”
Get full text

Cladribine and mitoxantrone dose escalation in indolent non-Hodgkin's lymphoma by Saven, A, Lee, T, Kosty, M, Piro, L

“…Since cladribine (2-chlorodeoxyadenosine [2-CdA]) and mitoxantrone both exhibit major activity against indolent lymphoid malignancies and have different…”
Get more information

Outpatient high-dose chemotherapy with autologous stem-cell rescue for hematologic and nonhematologic malignancies by Meisenberg, B R, Miller, W E, McMillan, R, Callaghan, M, Sloan, C, Brehm, T, Kosty, M P, Kroener, J, Longmire, R, Saven, A, Piro, L D

“…A prospective study to determine the feasibility of high-dose chemotherapy (HDC) and autologous stem-cell rescue (ASCR) in the outpatient setting. One hundred…”
Get more information

Relationship of Deoxycytidine Kinase and Cytoplasmic 5’-Nucleotidase to the Chemotherapeutic Efficacy of 2-Chlorodeoxyadenosine by Kawasaki, Hajime, Carrera, Carlos J., Piro, Lawrence D., Saven, Alan, Kipps, Thomas J., Carson, Dennis A.

“…The agent 2-chlorodeoxyadenosine (2-CdA) has chemotherapeutic activity in hairy cell leukemia (HCL) and in refractory chronic lymphocytic leukemia (CLL). The…”
Get full text

2-Chlorodeoxyadenosine activity in patients with untreated chronic lymphocytic leukemia by Saven, A, Lemon, R H, Kosty, M, Beutler, E, Piro, L D

“…2-chlorodeoxyadenosine (2-CdA; cladribine) is a purine analog with activity in patients with chronic lymphocytic leukemia (CLL) who fail to respond to…”
Get more information

Diagnostic Application of Two-Color Flow Cytometry in 161 Cases of Hairy Cell Leukemia by Robbins, Bruce A., Ellison, Douglas J., Spinosa, John C., Carey, Cristin A., Lukes, Robert J., Poppema, Sibrand, Saven, Alan, Piro, Lawrence D.

“…Recent immunophenotypic studies of hairy cell leukemia (HCL) have suggested specific patterns of immunoreactiv-ity that may aid in diagnosis. We studied…”
Get full text

An Open-label Pilot Trial of Cladibrine (2-Chlorodeoxyadenosine) in Patients with Primary Sclerosing Cholangitis by Duchini, A, Younossi, Z M, Saven, A, Bordin, G M, Knowles, H J, Pockros, P J

“…Cladribine (2-chlorodeoxyadenosine) is a nucleoside analog with specific antilymphocytic activity that has been used in patients with a variety of lymphoid…”
Get full text

Comparative efficacy of the newer nucleosides (fludarabine, 2'-deoxycoformycin, and 2-chlorodeoxyadenosine) in the treatment of indolent lymphoid malignancies by Saven, A

Get more information

Fludarabine treatment and transfusion-associated graft-versus-host disease by Saven, A

Get more information

Major activity of cladribine in patients with de novo B-cell prolymphocytic leukemia by Saven, A, Lee, T, Schlutz, M, Jacobs, A, Ellison, D, Longmire, R, Piro, L

“…De novo B-cell prolymphocytic leukemia (B-PLL) is a distinct clinicopathologic entity usually characterized by marked lymphocytosis, massive splenomegaly, an…”
Get more information

Activated integrin alpha v beta 3 cooperates with metalloproteinase MMP-9 in regulating migration of metastatic breast cancer cells by Rolli, M, Fransvea, E, Pilch, J, Saven, A, Felding-Habermann, B

“…Expression of adhesion receptor integrin alpha v beta 3 in an activated functional form strongly promotes metastasis in human breast cancer cells. Here, we…”
Get full text

Treatment of Hairy Cell Leukemia by Saven, Alan, Piro, Lawrence D.

Get full text

Immunomorphologic analysis of bone marrow biopsies after treatment with 2-chlorodeoxyadenosine for hairy cell leukemia by ELLISON, D. J, SHARPE, R. W, ROBBINS, B. A, SPINOSA, J. C, LEOPARD, J. D, SAVEN, A, PIRO, L. D

“…Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA) induces complete remissions in 85% of patients. Complete remission has been defined as the…”
Get full text

2-Chlorodeoxyadenosine: a potent antimetabolite with major activity in the treatment of indolent lymphoproliferative disorders by Saven, A, Piro, L D

“…2-Chlorodeoxyadenosine (2-CdA) is unique compared with traditional antimetabolites in that it is equally active against dividing and resting lymphocytes, which…”
Get more information

The Scripps Clinic experience with 2-chlorodeoxyadenosine in the treatment of hairy cell leukemia by Piro, L D, Ellison, D J, Saven, A

“…Follow-up data is now available on 144 patients with hairy cell leukemia treated with 2-chlorodeoxyadenosine (2-CdA) at the Scripps Clinic. Of 144 patients…”
Get more information

Pharmacokinetic study of oral and bolus intravenous 2-chlorodeoxyadenosine in patients with malignancy by Saven, A, Cheung, W K, Smith, I, Moyer, M, Johannsen, T, Rose, E, Gollard, R, Kosty, M, Miller, W E, Piro, L D

“…This study was designed to evaluate the absolute bioavailability (F value) of 2-chlorodeoxyadenosine (cladribine; 2-CdA) after multiple oral administrations,…”
Get more information

Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemia by Nieva, Jorge, Bethel, Kelly, Saven, Alan

“…Hairy cell leukemia (HCL) is an indolent B-cell neoplasm, strongly expressing CD20. Despite initial very high response rates following cladribine, many…”
Get full text